TY - JOUR
T1 - The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies
T2 - A review
AU - Krieckaert, Charlotte L.M.
AU - Bartelds, Geertje M.
AU - Lems, Willem F.
AU - Wolbink, Gerrit J.
PY - 2010/10/20
Y1 - 2010/10/20
N2 - Therapeutic monoclonal antibodies have revolutionized the treatment of various inflammatory diseases. Immunogenicity against these antibodies has been shown to be clinically important: it is associated with shorter response duration because of diminishing concentrations in the blood and with infusion reactions. Concomitant immunomodulators in the form of methotrexate or azathioprine reduced the immunogenicity of therapeutic antibodies in rheumatoid arthritis, Crohn disease, and juvenile idiopathic arthritis. The occurrence of adverse events does not increase when immunomodulators are added to therapeutic antibodies. The mechanism whereby methotrexate and azathioprine influence immunogenicity remains unclear. Evidence-based consensus on prescribing concomitant immunomodulators is needed.
AB - Therapeutic monoclonal antibodies have revolutionized the treatment of various inflammatory diseases. Immunogenicity against these antibodies has been shown to be clinically important: it is associated with shorter response duration because of diminishing concentrations in the blood and with infusion reactions. Concomitant immunomodulators in the form of methotrexate or azathioprine reduced the immunogenicity of therapeutic antibodies in rheumatoid arthritis, Crohn disease, and juvenile idiopathic arthritis. The occurrence of adverse events does not increase when immunomodulators are added to therapeutic antibodies. The mechanism whereby methotrexate and azathioprine influence immunogenicity remains unclear. Evidence-based consensus on prescribing concomitant immunomodulators is needed.
UR - http://www.scopus.com/inward/record.url?scp=79953281856&partnerID=8YFLogxK
U2 - https://doi.org/10.1186/ar3147
DO - https://doi.org/10.1186/ar3147
M3 - Review article
C2 - 21029481
SN - 1478-6354
VL - 12
SP - 217
JO - Arthritis Research and Therapy
JF - Arthritis Research and Therapy
IS - 5
M1 - 217
ER -